EGFR and non-small cell lung carcinoma: These in vivo data further support the roles of gefitinib-induced LPIN1 expression and NF-κB activation in cell survival (Figure 6D) and the importance of LPIN1 as a potential target to prevent gefitinib resistance in EGFR-mutant NSCLC.